X
X
Total 393357 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Boston naming test | assesses the ability to name pictures of objects through spontaneous responses and need for various types of cueing, inferences can be drawn regarding language facility and possible localization of cerebral damage. | ILX:0101395 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Botany | branch of biology concerned with plants. | ILX:0101396 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Botryoidal | Shape that is like the surface of a compact mass of grapes. | ILX:0101397 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Botulinum Toxin Type A | Purified botulinum toxin from Clostridium botulinum, purified from culture via dialysis and acid precipitation. Pharmacology: A 150 kDa neurotoxic protein produced from fermentation of Hall strain Clostridium botulinum type A grown in a medium containing casein hydrolysate, glucose and yeast extract. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin, and several accessory proteins. Botulinum Toxin Type A is not expected to be present in the peripheral blood at measurable levels following IM or intradermal injection at the recommended doses. The recommended quantities of neurotoxin administered at each treatment session are not expected to result in systemic, overt distant clinical effects, i.e. muscle weakness, in patients without other neuromuscular dysfunction. However, sub-clinical systemic effects have been shown by single-fiber electromyography after IM doses of botulinum toxins appropriate to produce clinically observable local muscle weakness. Mechanism of action: Botulinum Toxin Type A blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings. Drug type: Approved. Biotech. Investigational. Drug category: Anti-Wrinkle Agents. Antidystonic Agents. Neuromuscular Blocking Agents | ILX:0101398 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Botulinum Toxin Type B | Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps. Pharmacology: Botulinum Toxin Type B inhibits acetylcholine release at the neuromuscular junction via a three stage process: 1) Heavy Chain mediated neurospecific binding of the toxin, 2) internalization of the toxin by receptor-mediated endocytosis, and 3) ATP and pH dependent translocation of the Light Chain to the neuronal cytosol where it acts as a zinc-dependent endoprotease cleaving polypeptides essential for neurotransmitter release. Mechanism of action: Botulinum Toxin Type B binds to and cleaves the synaptic Vesicle Associated Membrane Protein (VAMP, also known as synaptobrevin) which is a component of the protein complex responsible for docking and fusion of the synaptic vesicle to the presynaptic membrane, a necessary step to neurotransmitter release. Drug type: Approved. Biotech. Drug category: Antidystonic Agents | ILX:0101399 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Botulism | A disease caused by potent protein NEUROTOXINS produced by CLOSTRIDIUM BOTULINUM which interfere with the presynaptic release of ACETYLCHOLINE at the NEUROMUSCULAR JUNCTION. Clinical features include abdominal pain, vomiting, acute PARALYSIS (including respiratory paralysis), blurred vision, and DIPLOPIA. Botulism may be classified into several subtypes (e.g., food-borne, infant, wound, and others) (MeSH). | ILX:0101400 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Bounding Box Annotation Units | Units of measure for the axes of the text bounding box. Defines whether or not the annotation is Image or Displayed Area relative. Both dimensions shall have the same units. | ILX:0101401 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Bounding Box Bottom Right Hand Corner | Location of the Bottom Right Hand Corner (BRHC) of the bounding box in which Unformatted Text Value (0070,0006) is to be displayed, in Bounding Box Annotation Units (0070,0003), given as columnrow. Column is the horizontal offset and row is the vertical offset. | ILX:0101402 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Bounding Box Text Horizontal Justification | Location of the Unformatted Test Value (0070,0006) relative to the vertical edges of the bounding box. | ILX:0101403 | 5 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Bounding Box Top Left Hand Corner | Location of the Top Left Hand Corner (TLHC) of the bounding box in which Unformatted Text Value (0070,0006) is to be displayed, in Bounding Box Annotation Units (0070,0003), given as columnrow. Column is the horizontal offset and row is the vertical offset. | ILX:0101404 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Bouton Quality | Refers to the morphology of a bouton. | ILX:0101405 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Bovidae | ILX:0101406 | 5 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Bovinae | ILX:0101407 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Bovine Spongiform Encephalopathy | A transmissible spongiform encephalopathy of cattle associated with abnormal prion proteins in the brain. Affected animals develop excitability and salivation followed by ATAXIA. This disorder has been associated with consumption of SCRAPIE infected ruminant derived protein. This condition may be transmitted to humans, where it is referred to as variant or new variant CREUTZFELDT-JAKOB SYNDROME (MeSH). | ILX:0101408 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Brachium of inferior colliculus | The Brachium of inferior colliculus (or inferior brachium) carries auditory afferent fibers from the inferior colliculus of the mesencephalon to the medial geniculate nucleus. [WP,unvetted]. | ILX:0101409 | 10 | scicrunch | 06/23/2020 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Brachium of superior colliculus | Bundle of fibers that passes over the medial geniculate nucleus (in humans) to reach the superior colliculus. Contains afferents from the retina. | ILX:0101410 | 10 | scicrunch | 06/23/2020 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Brachy Accessory Device ID | User or machine supplied identifier for Brachy Accessory Device. | ILX:0101411 | 5 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Brachy Accessory Device Name | User-defined name for Brachy Accessory Device. | ILX:0101412 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Brachy Accessory Device Nominal Thickness | Nominal thickness of Brachy Accessory Device (mm). See . | ILX:0101413 | 6 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Brachy Accessory Device Nominal Transmission | Nominal Transmission through Brachy Accessory Device (between 0 and 1). See . | ILX:0101414 | 6 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X